Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222145 | 0.88 | SLC2A1 (0.43) | SLC2A1CYP3A4LMNATSHRALDH1A1 | |
| SCHEMBL12894135 | 0.84 | ENPP2 (0.37) | SLC2A1PTGDR2CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL1222193 | 0.84 | SLC2A1 (0.38) | SLC2A1PTGDR2CSNK1DCSNK1ECYP2C9 | |
| SCHEMBL823506 | 0.84 | SLC2A1 (0.40) | SLC2A1CSNK1DCSNK1ECYP3A4CYP2C9 | |
| SCHEMBL823391 | 0.84 | TP53 (0.43) | SLC2A1CSNK1DCSNK1ECYP3A4CYP2C9 | |
| SCHEMBL823385 | 0.82 | NR1H4 (0.44) | PTGDR2TSHRALDH1A1KDM4EPOLB | |
| SCHEMBL823399 | 0.80 | LMNA (0.41) | SLC2A1CSNK1DCSNK1ECYP3A4CYP2C9 | |
| SCHEMBL1221953 | 0.80 | SLC2A1 (0.42) | SLC2A1CSNK1DCSNK1ECYP3A4CYP2C9 | |
| SCHEMBL823423 | 0.80 | SLC2A1 (0.40) | SLC2A1CSNK1DCSNK1ECYP3A4CYP2C9 | |
| SCHEMBL12894307 | 0.79 | SLC2A1 (0.39) | SLC2A1CSNK1DCSNK1ECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| WO-2010000032-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | SLC2A1 751/4885PTGDR2 3714/4885CSNK1D 889/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | SLC2A1 751/4885PTGDR2 3714/4885CSNK1D 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.